PDMR/Director Dealings & Holding(s) in Company
EKF, the AIM-listed global diagnostics business, announces that the Board of EKF has been informed that on Thursday 28 April 2022, certain funds connected to Christopher Mills, Non-executive Chairman, purchased a total of 1,275,000 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 35 pence per Ordinary Share.
Following this transaction, Christopher Mills' total direct and indirect interest in the Company is 132,150,000 Ordinary Shares, representing approximately 29.04% of the total voting rights over the Company's issued share capital.
The Notification of Dealing Form required in accordance with UK MAR is set out below as is the Standard form for notification of major holdings received by EKF today.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
For further information please contact:
|
EKF Diagnostics Holdings plc |
|||
|
Christopher Mills, Non-executive Chairman |
Tel: +44 (0)29 2071 0570 |
||
|
|||
|
|
|
||
|
Singer Capital Markets (Nominated Adviser & Joint Broker) |
Tel: +44 (0)20 7496 3000 |
||
|
Aubrey Powell / George Tzimas / Tom Salvesen |
|
||
|
|
|
||
|
Investec Bank plc (Joint Broker) |
Tel: +44 (0)20 7597 4000 |
||
|
Gary Clarence / Daniel Adams |
|
||
|
|
|
||
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or |
||
|
Paul McManus / Lianne Cawthorne |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
||
About EKF Diagnostics Holdings plc
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
|
Point-of-Care |
Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
|
Central Laboratory |
Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycates Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
|
Life Sciences |
Enzyme fermentation, Custom products and Bulk fermentation
|
|
Contract Manufacturing |
Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
|
Laboratory Services |
In September 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC (“ADL Health”), a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading ‘one stop’ provider of diagnostic products and services from sample collection to results. |
In May 2021, EKF announced its strategy for delivering growth to 2024 and beyond, and continuing to deliver shareholder value. The strategy for growth can be summarised as:
|
• |
continuing innovation in products and services in Point-of-Care, Central Laboratory and Life Sciences leveraging new and existing routes to market and relationships; |
|
• |
investment in expanded production and kitting capabilities to offer a suite of diagnostic Contract Manufacturing solutions to third party businesses; |
|
• |
expansion of CLIA Laboratories Testing offering, building on the acquired capabilities in ADL Health; and |
|
• |
identify complementary earnings-enhancing acquisitions with key strategic value. |
EKF will also continue to generate enhanced shareholder value through:
|
• |
a progressive dividend policy; and |
|
• |
its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us advanced access to innovative commercial opportunities and where we can build on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health plc.
|
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.